Home/Biofrontera/Jon Lyons, PhD, MBA
JL

Jon Lyons, PhD, MBA

Vice President of Scientific & Medical Affairs

Biofrontera

Therapeutic Areas

Biofrontera Pipeline

DrugIndicationPhase
BF-200 ALA (Ameluz®)Actinic Keratosis - PharmacokineticsN/A (Post-Approval)